Sanctioned drugs effectively suppress extension of lethal pathogen

Some currently approved drugs were found to suppress the growth of the amoeba Naegleria fowleri by inhibiting enzymes in the organism’s sterol biosynthesis pathway. Naegleria fowleri is a free-living amoeba found mainly in warm, under-chlorinated swimming pools, lakes, and rivers that can also act as an opportunistic pathogen causing the critical brain infection, primary amebic meningoencephalitis (PAM), in humans. The high transience rate of PAM (exceeding 97%) is accredited to (i) delayed diagnosis, (ii) lack of safe and effective anti-N. fowleri drugs, and (iii) the difficulty of delivering drugs to the brain. To enhance the therapeutic picture for treatment of N. fowleri infection, investigators at the University of California San Diego (USA) sought to identify new molecular targets that could link anti-Naegleria drug discovery to the existing pharmacopoeia of brain-penetrant drugs.¬†Original Link: